Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting

Table 2 Abnormal levels of biomarkers related to coagulation disorders in our study cohort (N: 235)

Variable	N	Mean (SD)	Patients with abnormal levels of biomarkers N (%)^a
DD	232	215.13 (174.47)	63 (27.0)
TAT	235	4.94 (3.23)	34 (40.0)
F 1 + 2	235	207.76 (81.18)	97 (41.3)
PAI-1	235	32.46 (23.61)	113 (48.1)
FVIII	235	131.28 (33.65)	29 (12.3)

PAI-1 plasminogen activator inhibitor type 1, F1 + 2 fragment 1 + 2, TAT thrombin antithrombin complex, FVIII factor VIII, DD d-dimer
^aCut-off values for case discrimination were defined upon the mean + 2SD of each biomarker as assessed in the control group (N: 150)

ISSN: 1479-5876